Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive May 1, 2005 Robert Ullmann	Back Page: Unhealthy Justice More than any other healthcare law, the Medicare/Medicaid exclusion statute has distorted our criminal justice system with government fraud investigations. This well-intentioned but misguided law should be repealed.
Chemistry World January 25, 2013 Andrew Turley	Allergan buys MAP for $958m Allergan, best known as the company behind Botox (onabotulinumtoxin A) injections, has agreed to buy US drug maker MAP Pharmaceuticals for $958 million
Chemistry World April 29, 2014 Phillip Broadwith	Valeant launches hostile bid for Allergan US drugmaker Valeant has lined up its next takeover target: Botox provider Allergan. Valeant has taken its proposal direct to shareholders, but Allergan has activated a 'poison pill' defense to buy time.
BusinessWeek October 13, 2003 Arlene Weintraub	He Bet on Botox -- And Won David Pyott transformed sleepy Allergan. Where is he taking its blockbuster drug?
CRM February 2003 David Myron	Support Gets a Face-Lift Allergan was able to automate the routing of 80 percent of all inbound, Web-generated emails, based on the business rules the company put in place.
Chemistry World November 24, 2014 Andy Extance	Actavis rescues Allergan with $66 billion deal The acrimonious seven-month battle over the future of US biotech Allergan looks to be over, after the Botox-maker accepted a 'white knight' takeover bid from Actavis.
The Motley Fool May 27, 2009 Brian Orelli	A Wrinkle in the Botox Plan The FDA turns down Allergan's label expansion, but it wasn't all bad news.
The Motley Fool January 31, 2007 Brian Lawler	No Earnings Face-Lift Needed For Allergan The ophthalmic and plastic surgery product developer has made many investors rich, and it's not stopping now.
The Motley Fool December 16, 2005 Stephen D. Simpson	A Romantic Rectangle in Health Care First Medicis wants Inamed, then Allergan wants Inamed. Now Mentor wants Medicis. Strange days in health care, to be sure. Investors, take note.
Bank Systems & Technology July 5, 2004 Cynthia Ramsaran	Dynamic Duo The CIO and CCO relationship is crucial in executing excellence in compliance.
IndustryWeek August 1, 2008	Software License Compliance: By The Numbers Most IT executives believe their companies would fail a software audit.
The Motley Fool June 5, 2008 Brian Lawler	Allergan Lashes Out The pharmaceutical announces a new drug that could promote eyelash growth.
The Motley Fool November 22, 2006 Brian Lawler	Implant Approval Gives Allergan a Lift The return of silicone breast implants continues. Shares of Allergan, best known for its Botox wrinkle treatment, were up nearly 8% on the news.
The Motley Fool September 12, 2008 Brian Lawler	A New Wrinkle for an Old Drug Allergan's muscle relaxant Botox performs well in two studies testing its ability to prevent migraine headaches.
IndustryWeek August 1, 2008 David Blanchard	Portrait of Best-in-Class Global Trade Compliance Trade compliance is taking on more prominence in separating the best companies from the also-rans.
Pharmaceutical Executive January 1, 2013 Ben Comer	Compliance in the C-Suite Compliance officers have risen into pharmaceutical management's highest ranks, by choice in some organizations, and by government decree in others. Either way, their importance as a strategic partner can hardly be understated.
Pharmaceutical Executive January 1, 2012	Compliance: Getting Those Ducks in a Row Pharma must coordinate the efforts of medical, legal, HR, global partners and many other players in the regulatory compliance space to keep itself afloat in choppy seas.
The Motley Fool May 6, 2009 Robert Steyer	Getting Ahead by Getting Rid of Wrinkles Medicis gets the FDA OK for an anti-wrinkle product as the market for Botox and other cosmetic skin drugs sags.
Pharmaceutical Executive September 1, 2005 Wilkenfeld & Braun-Davis	50 5 2005 Five things pharmaceutical companies can do to prepare for compliance in all 50 states.
Chemistry World July 29, 2015 Katrina Megget	Allergan steps away from generics with sale to Teva In something of a surprise move, Allergan has committed to selling its generics business to Israeli generics giant Teva for $40.5 billion, despite having no prior plans to sell.
Pharmaceutical Executive October 1, 2005 Andy Bender	Orchestrating Compliance Product managers at pharmaceuticals are not always happy to see their compliance officers. That may be changing.
The Motley Fool December 29, 2008 Brian Orelli	Thicker Lashes, Fatter Wallets The Food and Drug Administration approves Allergan's Latisse, a treatment for sparse eyelashes.
Chemistry World June 24, 2015 Matthew Gunther	Allergan to buy out Kythera Biopharma for $2.1bn The pharma firm Allergan will acquire Kythera Biopharmaceuticals in a $2.1 billion deal.
Financial Planning September 1, 2006 Jane Worthington	Accounting for Compliance Instead of viewing compliance as a necessary evil, financial advisors should see it as a cost of doing business and learn how to quantify that cost.
Chemistry World November 27, 2015 Anthony King	Pfizer and Allergan agree mega-merger The deal is being positioned as Irish-based Allergan taking over Pfizer, with the merged entity resident in Ireland for tax purposes.
The Motley Fool September 20, 2007 Brian Lawler	Allergan's Overactive Acquisition Specialty pharma Allergan announced yesterday that it is acquiring privately held Esprit Pharma for $370 million in an all-cash transaction. Investors, take note.
CIO May 4, 2009	The Judges of the 2009 Ones to Watch Awards Introducing the esteemed panel of judges, drawn from the ranks of the CIO Executive Council, who judged the 2009 awards.
Financial Planning October 1, 2009 Nancy Lininger	What It Takes Compliance is top of mind at many firms today. Here's what makes a great compliance officer, no matter who takes the role.
Chemistry World July 28, 2014 Andy Extance	Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover.
Wall Street & Technology August 27, 2004 Jessica Pallay	Building the Right Team With no sign of waning regulations, compliance officers remain essential to the architecture of the securities industry.
CIO November 1, 2009	2009 CIO Hall of Fame Finalists & Judges This Year's Hall of Fame honorees were judged by 15 former inductees. Our 13 finalists are also listed here.
IndustryWeek December 1, 2006 John Teresko	Still Not RoHS Compliant? Majority of companies don't have centralized compliance solution.
Bio-IT World January 12, 2004 Steve Lefar	Systematize Your Regulatory Info! Want better protection against regulation breaches? Build a system that engenders 'grassroots' compliance.
Chemistry World July 3, 2015 Phillip Broadwith	Job cuts at Allergan and Transgene Biotech firms Allergan and Transgene are both shuttering manufacturing facilities and laying off hundreds of staff.
The Motley Fool October 7, 2009 Jim Mueller	Daily Walk of Shame: Money-Hungry Drugmakers If Allergan wins its suit against the government, consumers will really be in trouble.
BusinessWeek December 25, 2006 Palmeri & Weintraub	Silicone Goes Subtle Allergan's campaign relies on friendly persuasion.
Wall Street & Technology July 1, 2005 Maria Santos	HP Eases Compliance Monitoring To provide CIOs with a solution for automated monitoring and reporting of compliance controls, Hewlett-Packard released OpenView Compliance Manager. The solution analyzes, compiles and reports compliance and IT risk information in a centralized dashboard view.
CIO October 11, 2012 Elizabeth Heichler	5 Things You Need to Know About Risk Management Risk is everywhere and if you're just trying to minimize it within IT, you're taking an additional risk. Follow these tips and learn how to take an intelligent approach to risk management.
Investment Advisor February 2008 Papa & Marks	The New Paradigm Integrating operations and compliance.
Wall Street & Technology August 27, 2004 Paul Allen	Custodians Target Compliance Firms that lack the technology, data or manpower to monitor compliance are looking to their custodian services for relief.
InternetNews August 1, 2007 Clint Boulton	Metastorm Merges With Proforma For Modeling Metastorm today agreed to buy partner Proforma, which provides modeling software to make business process management run smoother.
Financial Planning July 1, 2006 Jane Worthington	Compliance Tips: What Now? John Walsh, of the SEC's Office of Compliance Inspections and Examinations, offered these ten points for post-review discussions to attendees at NRS' Spring Compliance Conference.
CIO July 1, 2005 Edward Prewitt	Sox Compliance Now Business as Usual The effect of the Sarbanes-Oxley Act (Sox) on IT budgets is already receding, as compliance becomes just another cost of doing business, according to recent reports.
Wall Street & Technology May 30, 2007 Melanie Rodier	Market for Wealth Management Compliance Systems Set to Jump 15% by 2011 Investment advisors are expected to spend the most on technology as they are among the fastest growing and most regulated group of advisors. But hedge funds are also likely to increase IT spending.
Wall Street & Technology October 26, 2005 Katherine Heires	By the Dashboard Light As regulatory concerns persist, many financial firms are turning to dashboard technology to simplify compliance initiatives. Here are 12 key questions to ask before starting a compliance dashboard project.
Bank Technology News April 2004	By The Numbers When it comes to compliance technology spending, internal IT remains the biggest investment for financial institutions. But more firms are opting to buy rather than build.
Wall Street & Technology November 17, 2003 Ivy Schmerken	Holistic Compliance With a torrent of regulations raining down on them, Wall Street firms are wise to think about developing a global-compliance architecture. But can the chief compliance officer sell the project to senior management?